The American Association for the Study of Liver Diseases (AASLD) is preparing for its annual conference, The Liver Meeting. Set for November 7 to November 11, in Washington D.C., The Liver Meeting is an annual meeting of the global hepatology community. Attendees will have the opportunity to hear from world-class hepatology experts and learn about the latest breakthroughs in liver disease and tools for patient care.

For attendees interested in attending sessions that discuss primary biliary cholangitis (PBC), we have outlined all the sessions and events where PBC is a primary focus. The following dates and times are accurate as of October 9, 2025. For the most up-to-date schedule of events, visit The Liver Meeting's schedule page. 

Friday, November 7

The Capitol Challenge: Mastering PBC Care

  • 12:30 PM – 2:00 PM
  • Description: This symposium focuses on PBC and is designed to facilitate discussion between leaders in the field and attendees. By the end of the symposium, attendees will have developed skills in monitoring PBC disease activity and progression, identifying patients with PBC who require second-line therapy, and selecting evidence-based second-line therapies for patients with PBC. Attendees will emerge from the symposium with a greater confidence in their ability to tailor treatment for patients with PBC. 

Saturday, November 8

Primary Biliary Cholangitis (PBC) Patient Meet-Up

  • 9:45 AM – 10:45 AM
  • Description: At this meet-up event, attendees can look forward to an excellent opportunity to foster meaningful connections between the PBC patient community and health care clinicians. The event is a great way to build trust, deepen empathy, and strengthen collaboration.

Raising the Bar: Innovations in PBC Care

  • 12:30 PM – 2:00 PM
  • Description: During this interactive symposium, attendees will listen as experts offer their perspectives on advancing the standard of care for individuals living with PBC, particularly the strategies aimed at achieving normalization of biochemical markers, alleviating symptom burden, and exploring the potential role of novel therapies in improving outcomes. 

Sunday, November 9

Innovative Translational Studies in Cholestatic Disorders

  • 11:00 AM – 12:30 PM
  • Description: Attendees will learn about the roles played by multiple cell types in the pathogenesis of PBC and PSC. This session includes highlights of new discoveries in human and pre-clinical models of autoimmune and cholestatic disorders by the application of modern sophisticated analyses.

Advancing the Management of Cholestatic Liver Disease: Optimizing Treatment Pathways and Emerging Therapies

  • 12:30 PM – 2:00 PM
  • Description: During this session, world-class experts in adults and pediatric hepatology and gastroenterology will focus on PBC and progressive familial intrahepatic cholestasis (PFIC), specifically focusing on practical strategies and evidence-based tools to diagnose and facilitate tailored treatment decision making for the two diseases. 

Cholestatic Liver Diseases: New Treatments, Tools, and Symptoms Management

  • 2:00 PM – 3:30 PM
  • Description: In this session, specialists in PBC and primary sclerosing cholangitis (PSC) will collaborate with patient advocates to showcase newly available treatments for PBC, a new tool for patients to use on their first visit with their hepatologist, a new registry for patients with PSC, and what patients need to know about PBC and PSC symptom management.

General Update: Latest Advances in Hepatology

  • 2:00 PM – 3:30 PM
  • Description: During this session, presenters will focus on three key areas of hepatology: PBC, MASH, and alcohol-associated liver disease. Regarding PBC specifically, attendees will gain insights into the diagnosis and treatment of PBC, including the use of current therapies and effective monitoring strategies to enhance patient outcomes.

Evolving Approach to Second-Line Treatment in PBC: A Case-Based Discussion

  • 3:30 PM – 4:15 PM
  • Description: This session is set to highlight the ever-evolving approaches to second-line treatment in PBC through a case-based discussion. Attendees will receive practical insights and engage in a dynamic exchange between leading hepatologists. 
Monday, November 10

Global Consensus Primary Biliary Cholangitis (PBC) Endpoints - EASL / AASLD Joint Program

  • 11:00 AM – 12:30 PM
  • Description: The AASLD and the European Association for the Study of the Liver (EASL) have jointly led a multi-stakeholder Consensus Process focused on the use of surrogate endpoints and real-world evidence in the design of clinical trials for Primary Biliary Cholangitis (PBC). This collaborative initiative culminated in a Consensus Conference held during the 2025 EASL Congress in Amsterdam. This session will feature presentations of the final recommendations from this consensus process. 

Novel Therapies and Monitoring in Cholestatic Disease

  • 2:00 PM – 3:30 PM
  • Description: This session features a series of reports on the exploration of new agents in PBC and AIH, along with intriguing data on enhanced monitoring in cholestatic disorders. Attendees will also learn of potential roles for PPAR modulation in PBC.

Advancing Treatment in Primary Biliary Cholangitis (PBC): Insights into a Selective PPARδ Agonist

  • 3:30 PM – 4:15 PM
  • Description: This session features an FDA-approved treatment option for PBC. Attendees will gain insight into how the therapy may support improved PBC outcomes for patients affected by the disease. 

Sign up for alerts and stay informed on the latest clinical guidelines and guideline updates.

Copyright © 2025 Guideline Central, all rights reserved.